Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (2486)	5/2/2005 10:04:13 PM
From: SnowShredder	Read Replies (2) \| Respond to of 12215

Well, whatever they do, probably contributed to this private placement(from their home page)...bwdik? Best of Luck, SS >>>> MacroPore Biosurgery to Raise $11.0 Million from Equity Placement San Diego, CA, May 2, 2005 - MacroPore Biosurgery, Inc. (Frankfurt: XMP) today announced it has signed a definitive agreement to raise $11.0 million from the sale of 1.1 million shares of common stock at $10.00 per share. The transaction will be completed on or before May 31, 2005. As part of the agreement, the investor has been granted an option that expires December 31, 2006 to purchase an additional 2.2 million shares of common stock at $10.00 per share. In addition, the investor has been offered a voting seat on MacroPore’s Board of Directors. MacroPore will use these funds primarily to support the research and development of its regenerative cell technology. About MacroPore Biosurgery, Inc. MacroPore Biosurgery specializes in the discovery and development of regenerative medicine therapies. The Company has two principal technology platforms, adipose-derived regenerative cells and bioresorbable implants. The Company is developing treatments for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery using stem and regenerative cells from adipose tissue. This tissue is the richest and most accessible known source for regenerative cells. To facilitate the processing and delivery of adipose-derived regenerative cells, the Company is designing a proprietary point-of-care system, Celution™, to isolate and concentrate a patient’s own regenerative cells in real-time. Additionally, MacroPore Biosurgery manufactures the HYDROSORB™ family of FDA-cleared bioresorbable spine and orthopedic implants, which are distributed exclusively through Medtronic, Inc. For more information, please visit macropore.com. Contact: Stefanie Bacher Medien/Investoren International Tel. +1-858-736-5485 sbacher@macropore.com Tom Baker Medien/US-Investoren Tel. +1-858-458-0900 tbaker@macropore.com